{"id":9996,"date":"2026-01-05T06:41:01","date_gmt":"2026-01-05T12:41:01","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=9996"},"modified":"2026-02-24T06:41:48","modified_gmt":"2026-02-24T12:41:48","slug":"nanoscope-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2026\/01\/05\/nanoscope-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/","title":{"rendered":"Nanoscope Therapeutics presentar\u00e1 sus novedades en la 44.\u00aa Conferencia Anual de Atenci\u00f3n M\u00e9dica de JP Morgan."},"content":{"rendered":"
\n\t\t\t\t\t\t
\r\n\t\t\t\t\t\t\t\t
\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t
\r\n\r\n\t\t\t\t\r\n\t\t\t\t
\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

La empresa destacar\u00e1 los avances regulatorios,<\/i>\u00a0Impulso en los ensayos cl\u00ednicos y m\u00faltiples hitos que generar\u00e1n valor previstos para 2026.<\/i><\/h3>

DALLAS<\/span>,\u00a05 de enero de 2026<\/span>\u00a0\u2014\u00a0Nanoscopio Therapeutics Inc.<\/a>, una empresa de biotecnolog\u00eda comprometida con el desarrollo y la comercializaci\u00f3n de terapias novedosas e independientes de la enfermedad para pacientes con p\u00e9rdida de fotorreceptores y discapacidad visual debido a la degeneraci\u00f3n retiniana, anunci\u00f3 hoy que\u00a0Sulagna Bhattacharya, directora ejecutiva<\/a>, se presentar\u00e1 en el\u00a044th<\/sup>\u00a0Conferencia anual de JP Morgan sobre el sector sanitario<\/a>\u00a0en\u00a0Lunes, 12 de eneroth<\/sup>, 2026 de 11:30 a 11:55 AM PST.<\/b><\/p>

La Conferencia de Atenci\u00f3n M\u00e9dica de JP Morgan se celebrar\u00e1 del 12 al 15 de enero de 2026 en San Francisco, California, y el codiciado espacio para presentaciones del lunes por la ma\u00f1ana permite a las empresas con un importante impulso cl\u00ednico, regulatorio y comercial interactuar con sus socios durante el resto de la conferencia.<\/p>

Durante la presentaci\u00f3n, la Sra. Bhattacharya destacar\u00e1 el s\u00f3lido progreso regulatorio y cl\u00ednico de Nanoscope en\u00a0retinosis pigmentaria (RP)<\/b>, incluyendo el\u00a0inicio de una solicitud continua de licencia para productos biol\u00f3gicos (BLA)<\/b>\u00a0con la Administraci\u00f3n de Alimentos y Medicamentos de los Estados Unidos y el informe reciente\u00a0Resultados del seguimiento a tres a\u00f1os del estudio REMAIN.<\/b>\u00a0 Los resultados del estudio REMAIN demostraron mejoras visuales duraderas y cl\u00ednicamente significativas tras una \u00fanica inyecci\u00f3n intrav\u00edtrea de MCO-010, la principal terapia optogen\u00e9tica de Nanoscope para pacientes con retinosis pigmentaria.<\/p>

La Sra. Bhattacharya tambi\u00e9n describir\u00e1 Nanoscope.\u00a0Se prev\u00e9n m\u00faltiples hitos que generar\u00e1n valor en 2026.<\/b>, incluyendo el desarrollo cl\u00ednico continuo en\u00a0enfermedad de Stargardt (ES)<\/b>, y la expansi\u00f3n planificada hacia\u00a0atrofia geogr\u00e1fica (AG)<\/b>\u2014respaldando el potencial independiente de la enfermedad de la plataforma de opsina multicaracter\u00edstica (MCO) para potencialmente millones de pacientes en todo el mundo con p\u00e9rdida grave de la visi\u00f3n debido a la muerte de los fotorreceptores.<\/p>

\u201cLa Conferencia de Atenci\u00f3n M\u00e9dica de JP Morgan es el punto de encuentro donde convergen la ciencia, el capital y la convicci\u00f3n\u201d, declar\u00f3 la Sra. Bhattacharya. \u201cCon nuestra solicitud de licencia biol\u00f3gica (BLA) en marcha y con importantes hitos por delante en las \u00e1reas de retinosis pigmentaria, enfermedad de Stargardt y atrofia geogr\u00e1fica, 2026 es un a\u00f1o crucial para Nanoscope y un momento emocionante para asociarnos con inversores que comparten nuestra misi\u00f3n de ayudar a los pacientes que se han quedado sin opciones de tratamiento a recuperar una visi\u00f3n significativa\u201d.\u201d<\/p>

La gerencia estar\u00e1 disponible para reuniones en persona durante la conferencia. Para programar una reuni\u00f3n, comun\u00edquese con\u00a0bd@nanostherapeutics.com<\/a>.<\/p>

Acerca de la plataforma MCO
<\/b>MCO es una plataforma terap\u00e9utica intrav\u00edtrea de una sola aplicaci\u00f3n, ambulatoria y aplicable a cualquier enfermedad, dise\u00f1ada para restaurar la visi\u00f3n en pacientes con degeneraci\u00f3n de fotorreceptores, incluyendo retinosis pigmentaria (RP), enfermedad de Stargardt (ES) y atrofia geogr\u00e1fica (AG). Al activar las c\u00e9lulas bipolares de la retina, altamente densas, para que sean sensibles a la luz, MCO aprovecha el circuito visual restante tras la muerte de los fotorreceptores. El tratamiento con MCO no requiere pruebas gen\u00e9ticas, cirug\u00eda invasiva ni dosis repetidas, lo que permite una amplia aplicabilidad en pacientes dentro de los flujos de trabajo habituales en las consultas de retina.<\/p>

Acerca de Nanoscope Therapeutics
<\/b>Nanoscope Therapeutics est\u00e1 desarrollando una terapia optogen\u00e9tica restauradora de la visi\u00f3n, independiente de la enfermedad, para millones de pacientes ciegos por enfermedades degenerativas de la retina. Tras los resultados positivos del ensayo cl\u00ednico multic\u00e9ntrico, aleatorizado, doble ciego y controlado con placebo RESTORE Fase 2b\/3 para la retinosis pigmentaria (RP) (NCT04945772<\/a>), se ha iniciado una presentaci\u00f3n continua de BLA a la FDA. Si se aprueba, MCO-010 tiene el potencial de ser el tratamiento est\u00e1ndar para pacientes con RP, administrado como una inyecci\u00f3n \u00fanica en el consultorio sin necesidad de pruebas gen\u00e9ticas. La compa\u00f1\u00eda tambi\u00e9n ha mostrado resultados prometedores en el ensayo cl\u00ednico de fase 2 STARLIGHT de MCO-010 en la enfermedad de Stargardt (SD) (NCT05417126<\/a>) y planea iniciar una\u00a0Ensayo de registro de fase 3<\/a>\u00a0A principios de 2026, MCO-010 recibi\u00f3 las designaciones de v\u00eda r\u00e1pida y medicamento hu\u00e9rfano de la FDA para RP y SD, junto con la designaci\u00f3n RMAT para SD, y las designaciones de medicamento hu\u00e9rfano de la EMA para cubrir distrofias dominantes de bastones y conos no sindr\u00f3micas y sindr\u00f3micas, as\u00ed como distrofias maculares. Se espera que un programa de fase 2 para MCO en atrofia geogr\u00e1fica (GA) comience a principios de 2026. Otros programas listos para IND incluyen la amaurosis cong\u00e9nita de Leber (LCA).<\/p>

Contacto:
<\/b>Terap\u00e9utica del nanoscopio
(817) 857-1186
PR@nanostherapeutics.com<\/a><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"

Company to highlight regulatory progress,\u00a0clinical trial momentum,\u00a0and multiple value-driving milestones expected in 2026 DALLAS,\u00a0Jan. 5, 2026\u00a0\u2014\u00a0Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment due to retinal degeneration, announced today that\u00a0Sulagna Bhattacharya, Chief Executive Officer, will present at the\u00a044th\u00a0Annual J.P. Morgan Healthcare […]<\/p>\n","protected":false},"author":6,"featured_media":9998,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-9996","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"\nNanoscope Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2026\/01\/05\/nanoscope-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2026\/01\/05\/nanoscope-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-05T12:41:01+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-24T12:41:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/01\\\/05\\\/nanoscope-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/01\\\/05\\\/nanoscope-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference\",\"datePublished\":\"2026-01-05T12:41:01+00:00\",\"dateModified\":\"2026-02-24T12:41:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/01\\\/05\\\/nanoscope-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\\\/\"},\"wordCount\":578,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/01\\\/05\\\/nanoscope-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_JPMorgan_2026_V2.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/01\\\/05\\\/nanoscope-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/01\\\/05\\\/nanoscope-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\\\/\",\"name\":\"Nanoscope Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/01\\\/05\\\/nanoscope-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/01\\\/05\\\/nanoscope-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_JPMorgan_2026_V2.jpg\",\"datePublished\":\"2026-01-05T12:41:01+00:00\",\"dateModified\":\"2026-02-24T12:41:48+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/01\\\/05\\\/nanoscope-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/01\\\/05\\\/nanoscope-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/01\\\/05\\\/nanoscope-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_JPMorgan_2026_V2.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_JPMorgan_2026_V2.jpg\",\"width\":1200,\"height\":800},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/01\\\/05\\\/nanoscope-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope Therapeutics presentar\u00e1 sus novedades en la 44.\u00aa Conferencia Anual de Atenci\u00f3n M\u00e9dica de JP Morgan.","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2026\/01\/05\/nanoscope-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2026\/01\/05\/nanoscope-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2026-01-05T12:41:01+00:00","article_modified_time":"2026-02-24T12:41:48+00:00","og_image":[{"width":1200,"height":242,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Nanoscope Therapeutics","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2026\/01\/05\/nanoscope-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2026\/01\/05\/nanoscope-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference","datePublished":"2026-01-05T12:41:01+00:00","dateModified":"2026-02-24T12:41:48+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/01\/05\/nanoscope-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/"},"wordCount":578,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/01\/05\/nanoscope-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_JPMorgan_2026_V2.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2026\/01\/05\/nanoscope-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/","url":"https:\/\/nanostherapeutics.com\/2026\/01\/05\/nanoscope-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/","name":"Nanoscope Therapeutics presentar\u00e1 sus novedades en la 44.\u00aa Conferencia Anual de Atenci\u00f3n M\u00e9dica de JP Morgan.","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/01\/05\/nanoscope-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/01\/05\/nanoscope-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_JPMorgan_2026_V2.jpg","datePublished":"2026-01-05T12:41:01+00:00","dateModified":"2026-02-24T12:41:48+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2026\/01\/05\/nanoscope-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2026\/01\/05\/nanoscope-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2026\/01\/05\/nanoscope-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_JPMorgan_2026_V2.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_JPMorgan_2026_V2.jpg","width":1200,"height":800},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2026\/01\/05\/nanoscope-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"Terap\u00e9utica del nanoscopio"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/9996","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=9996"}],"version-history":[{"count":6,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/9996\/revisions"}],"predecessor-version":[{"id":10004,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/9996\/revisions\/10004"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/9998"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=9996"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=9996"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=9996"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}